CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 399 enrolled
Drug / intervention
LY3209590 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03736785
NCT03736785Phase 2Completed
CompareCT.gov

A Phase 2, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 2 Diabetes Mellitus Previously Treated With Basal Insulin

Eli Lilly and Company·interventional·Posted Nov 9, 2018·Updated Mar 8, 2021

In Brief

A Phase 2 clinical trial evaluating LY3209590 and Insulin Degludec for Type 2 Diabetes Mellitus. Completed, enrolled 399 participants across 44 sites in 3 countries.

Detailed Summary

The reason for this study is to see if the study drug LY3209590 is safe and effective in participants with type 2 diabetes that have already been treated with basal insulin.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesMexico, Puerto Rico, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedNov 9, 2018
Enrollment StartNov 15, 2018
Primary CompletionFeb 18, 2020
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 7.6 years ago

Interventions

LY3209590drug

Administered SC

Insulin Degludecdrug

Administered SC